Keywords: Clavis Pharma, Clovis Oncology, CP-4126, Pancretic cancer, Study failure, Development halted, Elacytarabine
Another pancreatic cancer drug hits the dust - Clavis/Clovis' CP-4126
Article | 12 November 2012
In yet another disappointment for pancreatic cancer patients, Norwegian cancer drug developer Clavis Pharma (OSE: CLAVIS), has suspended development of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
